文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

氟喹诺酮类最低抑菌浓度与吡嗪酰胺敏感性与耐多药结核临床改善相关:瑞典全国性队列研究

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该研究回顾性分析1992至2014年瑞典全国158例耐多药结核患者的临床与药敏数据,并对存档菌株行肉汤微量稀释法测定最低抑菌浓度(MIC)。结果显示83.5%(132/158)患者治疗成功,氟喹诺酮类MIC升高、糖尿病及年龄>40岁与治疗失败显著相关,接受吡嗪酰胺治疗者痰培养转阴时间显著缩短(中位差27天)。

要点

  • 氟喹诺酮类MIC升高与耐多药结核治疗失败显著相关。
  • 接受吡嗪酰胺治疗者痰培养转阴时间较未接受者缩短27天。
  • 糖尿病和年龄>40岁亦与不良治疗结局显著相关。

核心结论

  • 氟喹诺酮类MIC升高与耐多药结核患者治疗失败相关。
  • 吡嗪酰胺治疗与更短的痰培养转阴时间相关,提示吡嗪酰胺药敏试验的重要性。

研究设计与样本

  • 瑞典全国性回顾性队列研究,纳入1992至2014年耐多药结核患者158例。
  • 对存档的个体结核分枝杆菌分离株采用Middlebrook 7H9肉汤微量稀释法回顾性测定MIC。
  • 采用Cox比例风险模型分析MIC、药敏结果及临床变量与痰培养转阴时间和治疗结局的关系。

主要发现

  • 83.5%(132/158)的耐多药结核患者获得成功治疗结局。
  • 氟喹诺酮类MIC升高、糖尿病和年龄>40岁与治疗失败显著相关。
  • 接受吡嗪酰胺治疗的患者痰培养转阴时间较未接受者显著缩短,中位差27天。

临床怎么用

  • 对耐多药结核患者可考虑测定氟喹诺酮类MIC以评估耐药程度和预后。
  • 应重视吡嗪酰胺药敏试验,因其治疗与更短的痰培养转阴时间相关。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimum inhibitory concentration (MIC) testing, unlike routine drug susceptibility testing (DST) at a single critical concentration, quantifies drug resistance. The association of MICs and treatment outcome in multidrug-resistant (MDR)-tuberculosis patients is unclear. Therefore, we correlated MICs of first- and second-line tuberculosis drugs with time to sputum culture conversion (tSCC) and treatment outcome in MDR-tuberculosis patients. METHODS: Clinical and demographic data of MDR-tuberculosis patients in Sweden, including DST results, were retrieved from medical records from 1992 to 2014. MIC determinations were performed retrospectively for the stored individual Mycobacterium tuberculosis (Mtb) isolates using broth microdilution in Middlebrook 7H9. We fitted Cox proportional hazard models correlating MICs, DST results, and clinical variables to tSCC and treatment outcome. RESULTS: Successful treatment outcome was observed in 83.5% (132/158) of MDR-tuberculosis patients. Increasing MICs of fluoroquinolones, diabetes, and age >40 years were significantly associated with unsuccessful treatment outcome. Patients treated with pyrazinamide (PZA) had a significantly shorter tSCC compared to patients who were not (median difference, 27 days). CONCLUSIONS: Increasing MICs of fluoroquinolones were correlated with unsuccessful treatment outcome in MDR-tuberculosis patients. Further studies, including MIC testing and clinical outcome data to define clinical Mtb breakpoints, are warranted. PZA treatment was associated with shorter tSCC, highlighting the importance of PZA DST.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Forsman LD, Jonsson J, Wagrell C, et al. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades. Clin Infect Dis. 2019. PMID: 30561569. doi:10.1093/cid/ciy1068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。